(DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 118 | Myelomeningocele | 9 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04652908 (ClinicalTrials.gov) | February 2021 | 25/11/2020 | Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial | Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele | Myelomeningocele | Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix | Diana Lee Farmer | California Institute for Regenerative Medicine (CIRM) | Not yet recruiting | 19 Weeks | 25 Weeks | All | 35 | Phase 1;Phase 2 | NULL |
| 2 | JPRN-UMIN000040088 | 2019/07/01 | 07/04/2020 | Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele | Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele - Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele | Myelomeningocele | MMC(Myelomeningocele) open fetal surgery | OSAKA UniversityDepartment of MedicineDivision of Obstetrics and Gynecology | NULL | Recruiting | 20years-old | Not applicable | Female | 15 | Not selected | Japan |
| 3 | NCT04027374 (ClinicalTrials.gov) | July 1, 2019 | 16/7/2019 | Stress-associated Epigenetic Alterations in Newborns After Fetal Surgery | Epigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory Study | Meningomyelocele | Procedure: Fetal surgery for MMC repair | University Children's Hospital, Zurich | University of Zurich;Psychiatric University Hospital, Zurich | Recruiting | N/A | 3 Months | All | 90 | Switzerland | |
| 4 | NCT03936322 (ClinicalTrials.gov) | May 7, 2019 | 1/5/2019 | Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study | Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study | Spina Bifida;Myelomeningocele;Neural Tube Defects | Device: Minimally invasive fetoscopic repair of MMC | Mayo Clinic | NULL | Enrolling by invitation | 18 Years | N/A | Female | 15 | N/A | United States |
| 5 | NCT04362592 (ClinicalTrials.gov) | November 2, 2018 | 24/3/2020 | In-Utero Endoscopic Correction of Spina Bifida | In-Utero Endoscopic Correction of Spina Bifida: Laparotomy or Percutaneous | Neural Tube Defects;Spina Bifida;Myelomeningocele | Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique;Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique | University of Southern California | NULL | Recruiting | 18 Years | 52 Years | Female | 33 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02390895 (ClinicalTrials.gov) | May 17, 2017 | 15/2/2015 | Prenatal Endoscopic Repair of Fetal Spina Bifida | Prenatal Endoscopic Repair of Fetal Spina Bifida | Myelomeningocele | Procedure: endoscopic repair of myelomeningocele before 26 SA | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | N/A | Female | 15 | N/A | France |
| 7 | NCT04468568 (ClinicalTrials.gov) | January 8, 2017 | 1/3/2020 | In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline | Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele | Myelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous System | Drug: Atosiban;Drug: Terbutaline | University of Sao Paulo General Hospital | NULL | Recruiting | 18 Years | 40 Years | Female | 28 | N/A | Brazil |
| 8 | NCT04186338 (ClinicalTrials.gov) | December 1, 2016 | 2/12/2019 | Daily Physical Activity in Myelomeningocele | Daily Physical Activity in Children and Adolescents With Low Lumbar and Sacral Level Myelomeningocele | Physical Activity | Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics) | Marmara University | NULL | Completed | 6 Years | 16 Years | All | 20 | NULL | |
| 9 | NCT00175123 (ClinicalTrials.gov) | May 2005 | 9/9/2005 | Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele | Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele | Myelomeningocele;Bladder, Neurogenic | Drug: Botulinum A toxin | University of Aarhus | Aarhus University Hospital | Active, not recruiting | 2 Years | 16 Years | Both | 30 | Phase 4 | Denmark |